Facebook Instagram Pinterest Reddit Tumblr X Youtube
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Search
Sign in
Welcome! Log into your account
Forgot your password? Get help
Password recovery
Recover your password
A password will be e-mailed to you.
PsyNews.com
  • Home
  • About
  • News
  • Events
  • Shop
  • Directory
  • Contact Us
Home Featured Page 273

Featured

Latest
  • Latest
  • Featured posts
  • Most popular
  • 7 days popular
  • By review score
  • Random

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly; Turnbull Doubles Down on BOL-148; Compass Talks Indication Expansion, Could VA Help?

From Sonora to Big Pharma: Kimon de Greef Traces the Strange Rise of 5-MeO-DMT

Psychedelic Alpha Crossword: Summer 2026

Weekly Psychedelic Policy Briefing – August 2, 2026

Mareesa Stertz – Sphinx Gate Beyond Burning Man: Psychedelic Healing Without Psychedelics

Revive Therapeutics Enters into Feasibility Agreement with LTS Lohmann to Develop...

Bright Minds Biosciences Shares to Commence Trading on the OTCQB Venture...

Algernon Pharmaceuticals Receives Positive Feedback from U.S. FDA for Psychedelic Drug...

PharmaTher Announces FDA Approval of Ketamine IND In The Treatment of...

MindMed Receives FDA Type C Meeting Response for Project Lucy Phase...

BetterLife Announces Closing of a Non-Brokered Private Placement

Entheon Biomedical Corp. Provides Corporate Update

MindMed Announces 2021 Q1 Financial Results; Cash Balance of $160m USD...

Psychedelic Bulletin: MAPS Study Published in Nature Medicine; Numinus’ Hiring Spree;...

PTSF59 – Bipolar and Psychedelics, with Benjamin Mudge

Load more

EDITOR PICKS

Pα+ Psychedelic Bulletin #229: SAMHSA Convenes Experts; AtaiBeckley’s Road to Lilly;...

From Sonora to Big Pharma: Kimon de Greef Traces the Strange...

Psychedelic Alpha Crossword: Summer 2026

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY

    ABOUT US
    PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.
    FOLLOW US
    Facebook Instagram Pinterest Reddit Tumblr X Youtube
    ©